Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c

Published:2023-10 Issue: Volume:166 Page:115304
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Loos Nancy H.C.,Retmana Irene A.,Rijmers Jamie,Wang Yaogeng,Gan Changpei,Lebre Maria C.,Sparidans Rolf W.,Beijnen Jos H.,Schinkel Alfred H.

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference49 articles.

1. Identification of the clinical development candidate MRTX849, a covalent KRAS(G12C) inhibitor for the treatment of cancer;Fell;J. Med. Chem.,2020

2. The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients;Hallin;Cancer Discov.,2020

3. KRAS mutation: from undruggable to druggable in cancer;Huang;Signal Transduct. Target Ther.,2021

4. H.A. Blair, Sotorasib: First Approv. Drugs 81 13 2021 1573 1579.

5. Sotorasib for lung cancers with KRAS p.G12C mutation;Skoulidis;New Engl. J. Med.,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of the antitumor drugs adagrasib and asciminib on apixaban metabolism in vitro and in vivo;Chemico-Biological Interactions;2024-08

2. Application of newly developed and validated LC-MS/MS method for pharmacokinetic study of adagrasib and pembrolizumab simultaneously in rat plasma;Journal of Chromatography B;2024-07

3. ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure;Biomedicine & Pharmacotherapy;2024-06

4. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies;Signal Transduction and Targeted Therapy;2023-12-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3